Literature DB >> 30842333

Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1+ and TIGIT+ CD4 T Cells.

George N Llewellyn1, Eduardo Seclén1, Stephen Wietgrefe2, Siyu Liu3, Morgan Chateau1, Hua Pei3, Katherine Perkey2, Matthew D Marsden4,5, Sarah J Hinkley6, David E Paschon6, Michael C Holmes6, Jerome A Zack4,5, Stan G Louie3, Ashley T Haase2, Paula M Cannon7.   

Abstract

Combination anti-retroviral drug therapy (ART) potently suppresses HIV-1 replication but does not result in virus eradication or a cure. A major contributing factor is the long-term persistence of a reservoir of latently infected cells. To study this reservoir, we established a humanized mouse model of HIV-1 infection and ART suppression based on an oral ART regimen. Similar to humans, HIV-1 levels in the blood of ART-treated animals were frequently suppressed below the limits of detection. However, the limited timeframe of the mouse model and the small volume of available samples makes it a challenging model with which to achieve full viral suppression and to investigate the latent reservoir. We therefore used an ex vivo latency reactivation assay that allows a semiquantitative measure of the latent reservoir that establishes in individual animals, regardless of whether they are treated with ART. Using this assay, we found that latently infected human CD4 T cells can be readily detected in mouse lymphoid tissues and that latent HIV-1 was enriched in populations expressing markers of T cell exhaustion, PD-1 and TIGIT. In addition, we were able to use the ex vivo latency reactivation assay to demonstrate that HIV-specific TALENs can reduce the fraction of reactivatable virus in the latently infected cell population that establishes in vivo, supporting the use of targeted nuclease-based approaches for an HIV-1 cure.IMPORTANCE HIV-1 can establish latent infections that are not cleared by current antiretroviral drugs or the body's immune responses and therefore represent a major barrier to curing HIV-infected individuals. However, the lack of expression of viral antigens on latently infected cells makes them difficult to identify or study. Here, we describe a humanized mouse model that can be used to detect latent but reactivatable HIV-1 in both untreated mice and those on ART and therefore provides a simple system with which to study the latent HIV-1 reservoir and the impact of interventions aimed at reducing it.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV-1; PD-1; TALEN; TIGIT; humanized mice; latency

Mesh:

Substances:

Year:  2019        PMID: 30842333      PMCID: PMC6498059          DOI: 10.1128/JVI.02086-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  109 in total

1.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

2.  T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway.

Authors:  Young Kyeung Kim; Uri Mbonye; Joseph Hokello; Jonathan Karn
Journal:  J Mol Biol       Date:  2011-07-29       Impact factor: 5.469

3.  Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection.

Authors:  T Schacker; S Little; E Connick; K Gebhard; Z Q Zhang; J Krieger; J Pryor; D Havlir; J K Wong; R T Schooley; D Richman; L Corey; A T Haase
Journal:  J Infect Dis       Date:  2001-01-17       Impact factor: 5.226

4.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

5.  High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects.

Authors:  Maria Iglesias-Ussel; Claire Vandergeeten; Luigi Marchionni; Nicolas Chomont; Fabio Romerio
Journal:  J Virol       Date:  2013-06-12       Impact factor: 5.103

6.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

Authors:  Ole S Søgaard; Mette E Graversen; Steffen Leth; Rikke Olesen; Christel R Brinkmann; Sara K Nissen; Anne Sofie Kjaer; Mariane H Schleimann; Paul W Denton; William J Hey-Cunningham; Kersten K Koelsch; Giuseppe Pantaleo; Kim Krogsgaard; Maja Sommerfelt; Remi Fromentin; Nicolas Chomont; Thomas A Rasmussen; Lars Østergaard; Martin Tolstrup
Journal:  PLoS Pathog       Date:  2015-09-17       Impact factor: 6.823

7.  HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells.

Authors:  Leonard Chavez; Vincenzo Calvanese; Eric Verdin
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

8.  Persistent Viral Reservoirs in Lymphoid Tissues in SIV-Infected Rhesus Macaques of Chinese-Origin on Suppressive Antiretroviral Therapy.

Authors:  Summer Siddiqui; Stefanie Perez; Yong Gao; Lara Doyle-Meyers; Brian T Foley; Qingsheng Li; Binhua Ling
Journal:  Viruses       Date:  2019-01-27       Impact factor: 5.048

9.  HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model.

Authors:  Jenna B Honeycutt; Angela Wahl; Nancie Archin; Shailesh Choudhary; David Margolis; J Victor Garcia
Journal:  Retrovirology       Date:  2013-10-24       Impact factor: 4.602

10.  Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV.

Authors:  Alison L Hill; Daniel I S Rosenbloom; Edward Goldstein; Emily Hanhauser; Daniel R Kuritzkes; Robert F Siliciano; Timothy J Henrich
Journal:  PLoS Pathog       Date:  2016-04-27       Impact factor: 6.823

View more
  10 in total

1.  Inducing Long-Term HIV-1 Latency in the TKO-BLT Mouse Model.

Authors:  Yunyun Di; Kerry J Lavender
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Perspectives on Non-BLT Humanized Mouse Models for Studying HIV Pathogenesis and Therapy.

Authors:  Kazutaka Terahara; Ryutaro Iwabuchi; Yasuko Tsunetsugu-Yokota
Journal:  Viruses       Date:  2021-04-28       Impact factor: 5.048

Review 3.  Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.

Authors:  Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2022-01-12

4.  Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.

Authors:  Matthew D Marsden; Tian-Hao Zhang; Yushen Du; Melanie Dimapasoc; Mohamed S A Soliman; Xiaomeng Wu; Jocelyn T Kim; Akira Shimizu; Adam Schrier; Paul A Wender; Ren Sun; Jerome A Zack
Journal:  Cell Rep Med       Date:  2020-12-22

Review 5.  Humanized Mice for the Evaluation of Novel HIV-1 Therapies.

Authors:  Shawn Abeynaike; Silke Paust
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

6.  Embryonic and early postnatal cranial bone volume and tissue mineral density values for C57BL/6J laboratory mice.

Authors:  Kate M Lesciotto; Lauren Tomlinson; Steven Leonard; Joan T Richtsmeier
Journal:  Dev Dyn       Date:  2022-02-07       Impact factor: 2.842

7.  Three-dimensional models of the cervicovaginal epithelia to study host-microbiome interactions and sexually transmitted infections.

Authors:  Vonetta L Edwards; Elias McComb; Jason P Gleghorn; Larry Forney; Patrik M Bavoil; Jacques Ravel
Journal:  Pathog Dis       Date:  2022-08-27       Impact factor: 3.951

Review 8.  Humanized Mice for Infectious and Neurodegenerative disorders.

Authors:  Prasanta K Dash; Santhi Gorantla; Larisa Poluektova; Mahmudul Hasan; Emiko Waight; Chen Zhang; Milica Markovic; Benson Edagwa; Jatin Machhi; Katherine E Olson; Xinglong Wang; R Lee Mosley; Bhavesh Kevadiya; Howard E Gendelman
Journal:  Retrovirology       Date:  2021-06-05       Impact factor: 3.768

9.  Transient HIV Reservoirs and Interleukin-6 Increase After Anti-Programmed Death-1 Antibody Infusion in HIV Patients with Lung Cancer.

Authors:  Xiaorong Peng; Ran Tao; Ying Chen; Junwei Su; Ying Huang; Biao Zhu
Journal:  J Inflamm Res       Date:  2022-01-10

Review 10.  Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.

Authors:  Yuting Sun; Jing Xue
Journal:  Viruses       Date:  2022-03-11       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.